ADMP Adamis Pharmaceuticals Corporation

0.52
+0.01  (+1%)
Previous Close 0.52
Open 0.52
Price To Book 0.8
Market Cap 32,182,217
Shares 61,633,809
Volume 68,691
Short Ratio
Av. Daily Volume 2,061,947
Stock charts supplied by TradingView

NewsSee all news

  1. Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI

    SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Adamis") today announced that after the close of U.S. markets on November 22nd, it received a Complete Response Letter

  2. Adamis Pharmaceuticals Announces Publication of Comparative Pharmacokinetics of Community Use Naloxone Formulations

    SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Adamis") announced today that an article entitled "Comparative Pharmacokinetic Analysis of Community Use Naloxone

  3. Adamis Pharmaceuticals Announces Third Quarter 2019 Financial Results and Business Update

    SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced financial results for the third quarter ended September 30, 2019 and provided a business update. Dr. Dennis

  4. Adamis Pharmaceuticals Schedules Third Quarter 2019 Earnings Conference Call and Business Update

    SAN DIEGO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") announced today that it will host an investor conference call on Tuesday, November 12, 2019 at 2:00 pm

  5. Adamis Pharmaceuticals Provides Regulatory Update for Its Higher Dose Naloxone Pre-Filled Syringe

    SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Adamis") today announced that as of the close of business today, Adamis has not received any notice of action from the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
Epinephrine Pre-filled Syringe (PFS)
Emergency treatment of anaphylaxis.
Phase 3 development on hold - noted May 9, 2019.
APC-1000
Asthma/COPD
FDA Approval announced September 27, 2018.
Symjepi - low dose
Anaphylaxis
CRL announced November 25, 2019.
Higher Dose Naloxone Injection
Opioid overdose
Refusal to file letter received February 26, 2019.
APC-8000 (sublingual tadalafil)
Erectile dysfunction

Latest News

  1. Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI

    SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Adamis") today announced that after the close of U.S. markets on November 22nd, it received a Complete Response Letter

  2. Adamis Pharmaceuticals Announces Publication of Comparative Pharmacokinetics of Community Use Naloxone Formulations

    SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Adamis") announced today that an article entitled "Comparative Pharmacokinetic Analysis of Community Use Naloxone

  3. Adamis Pharmaceuticals Announces Third Quarter 2019 Financial Results and Business Update

    SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced financial results for the third quarter ended September 30, 2019 and provided a business update. Dr. Dennis

  4. Adamis Pharmaceuticals Schedules Third Quarter 2019 Earnings Conference Call and Business Update

    SAN DIEGO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") announced today that it will host an investor conference call on Tuesday, November 12, 2019 at 2:00 pm

  5. Adamis Pharmaceuticals Provides Regulatory Update for Its Higher Dose Naloxone Pre-Filled Syringe

    SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Adamis") today announced that as of the close of business today, Adamis has not received any notice of action from the

  6. Adamis Pharmaceuticals Announces Presentation of ZIMHI data at IHV Scientific Meeting

    SAN DIEGO, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Adamis") announced today the presentation of data pertaining to its investigational high dose naloxone product (ZIMHI) at

  7. Adamis Pharmaceuticals Announces Commercial Partnership with Emerge Health for SYMJEPI® in Australia and New Zealand

    SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) announced today that it has entered into an exclusive distribution and commercialization agreement with Emerge Health Pty

  8. Adamis Pharmaceuticals Announces Presentation Pertaining to Its High Dose Naloxone Product Candidate at IHV Scientific Meeting

    SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) announced today that Dr. Ronald Moss, Chief Medical Officer, will be presenting data on October 4, 2019, pertaining to the

  9. Adamis Pharmaceuticals Provides Update for Naloxone Product Candidate

    SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) announced today the completion of pharmacokinetic (PK) studies comparing its naloxone injection product candidate, ZIMHITM

  10. Adamis Pharmaceuticals Provides Launch and Marketing Update for SYMJEPI

    SAN DIEGO, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today provided a progress report and marketing update on the U.S. launch of SYMJEPITM (epinephrine) 0.3 mg and 0.15 mg

  11. Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors

    SAN DIEGO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the appointment of Howard C. Birndorf and Roshawn Blunt to its Board of Directors. Dr. Dennis J. Carlo,